Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Piperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL631560 | 1.00 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Piperidine SCHEMBL16927692 | 0.98 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Pyrrolidine SCHEMBL2531422 | 0.98 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Pyrrolidine SCHEMBL16241174 | 0.96 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Azetidine SCHEMBL28290955 | 0.94 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Aziridine SCHEMBL5185484 | 0.92 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Piperazine SCHEMBL7635861 | 0.90 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Piperazine SCHEMBL5875357 | 0.90 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Cyclohexane SCHEMBL27563472 | 0.88 | GAA (0.54) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Cyclopropane SCHEMBL2101355 | 0.88 | GAA (0.54) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414057-B2 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1539735-A4 | PIPERAZINE UREA DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20060040906-A1 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-02-23 | — | — | US | disclosed |
| EP-1539735-A1 | PIPERAZINE UREA DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024720-A1 | PIPERAZINE UREA DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040906-A1 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC1R | ALDH1A1 3345/4885SMN1; SMN2 4423/4885LMNA 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.